Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MPLX LP (MPLX) vs ResMed Inc. (RMD) Price & Performance

ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

MPLX LP vs ResMed Inc. — how do they compare? MPLX LP trades at $59.9 (market cap $60.12B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.26%). Which is the better fit depends on your goals.

MPLXRMD
Market Cap
$60.12B$32.61B
Sector
TechnologyHealth
52-Week High
$60.51$293.73
52-Week Low
$47.80$182.82
Enterprise Value
$85.22B$31.97B
Dividend Yield
7.26%1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MPLX LP

MPLX trades at $59.94, up 2.11% today, with a bullish technical signal from moving averages and a consensus analyst price target of $61.50. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly earnings have missed expectations. A recent $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) supports growth initiatives, while a 7.3% dividend yield attracts income investors.

Outlook remains positive given fee-based revenue stability and growth projects, but risks include execution challenges from higher capital spending and leverage. Analyst sentiment is strongly bullish with no sell ratings, though investors should monitor earnings consistency and debt levels amid volatile energy markets.

ResMed Inc.

ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.

Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MPLX LP

MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.

Read more on MPLX

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD